Covaxin maker Bharat Biotech's nasal vaccine ready to take on new covid strains
India has recorded 5,755 active covid cases, according to the Union health ministry's data issued on Sunday. The nation also reported four new fatalities in the last 24 hours, taking the total covid death toll since 1 January to 59.
Health officials have identified two new JN.1 covid variants as the cause of the fresh wave of the infectious disease.
Suchrita Ella, managing director of Bharat Biotech, said the company's nasal vaccine iNCOVACC is 'specifically designed for flexibility to adapt to circulating strains, protection in upper respiratory tract, and easy administration without injections".
'Bharat Biotech's covid-19 vaccine platforms, both the injectable and intranasal versions, are enabled for adaptation. However, any decision to restart production is contingent upon regulatory agency approvals," she said in an email interview.
'We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," Ella said, adding that the company is monitoring the situation and is "well positioned to respond effectively".
Also read | Covid cases are rising again. Should we be worried?
Bharat Biotech and Serum Institute of India manufactured billions of doses of vaccines for Indians and for supplying to more than 100 countries during the first few waves of the covid pandemic. The last covid vaccine batches were manufactured a year ago, with no visibility on new stocks.
Dr. Soumya Swaminathan, a former chief scientist at the World Health Organization (WHO), recently emphasized the need for vaccine manufacturers to update their formulas based on new variants, warning that vaccines developed for the original covid strain would offer little protection now.
Bharat Biotech halted production of covaxin due to a decline in demand in early 2022 and destroyed significant quantities of its vaccine stock. 'Subsequently, we proceeded with the destruction of about 200 million doses of bulk and about 50 million doses of vaccines in vials," Ella said.
Asked if booster doses should be given to high-risk populations, Ella said that remained subject to national regulatory approval.
Also read | India steps up surveillance as covid-19 cases surge in Hong Kong and Singapore
India's covid preparedness
The Union health ministry, while stating that most current covid cases are mild, has directed states and union territories to increase testing and ensure medical preparedness across health facilities, reviewing the availability of oxygen, isolation beds, ventilators, and essential medicines.
A nationwide mock drill was conducted last week to assess the functionality of oxygen supply systems in hospitals.
The Union government has also advised the public to practise covid-appropriate behaviour, especially avoiding crowded places when unwell and seeking medical intervention.
State and district surveillance units are also closely monitoring cases of influenza-like illness (ILL) and severe acute respiratory illness (SARI). As per government guidelines, all admitted SARI patients and 5% of ILI cases are to be tested for covid.
Scientists at the Indian Council of Medical Research (ICMR) are conducting genome sequencing of positive samples to track the variants.
The latest covid wave is attributed to two new coronavirus variants—NB.1.8.1 and LF.7, which are mutations of the Omicron offspring JN.1 variant. Kerala has reported the maximum number of covid cases this year, at 1,373, followed by Maharashtra (510), Delhi (457), Gujarat (461), and West Bengal (431).
According to the Union health ministry, 760 people have recovered from covid in the last 24 hours, bringing the total number of recoveries this year to 5,484.
Also read | The official 'data fog' on India's covid toll has finally cleared up. Here's what we know now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
It's time to fix health insurance for India's ‘missing middle'. Here's how to do it.
India has made commendable progress in expanding healthcare access, especially for economically weaker, sections through initiatives such as Ayushman Bharat. However, a large segment remains inadequately protected—the uninsured and underinsured middle class. Roughly 8 to 10 crore Indian households fall into this 'missing middle". They are too affluent for subsidised schemes but unable to afford adequate private insurance. As healthcare costs rise steadily, this group is increasingly vulnerable to financial distress during medical emergencies. The current retail health insurance model is structurally flawed. The typical ₹5-10 lakh cover that most families buy appears sufficient but loses value over time as healthcare inflation averages 10-12% annually. In a decade, the real value of this cover falls drastically. Premiums also rise sharply with age. For those above 55 or 60, premiums can exceed 20% of the sum insured—an unsustainable cost when health risks are highest. Health insurance, ironically, becomes least viable when it is needed most. Pre-existing conditions such as diabetes and hypertension—common among Indians over 45—further raise the barrier to new coverage. High distribution costs inflate premiums without adding value. Insurers also lack leverage with hospitals, leading to inflated treatment costs, higher claims, and rising premiums. How to fix this Yet, India has the building blocks to create a better model. The government has already laid the foundation for a voluntary, contributory, government-facilitated insurance scheme for middle India. First, Ayushman Bharat has negotiated cost-effective treatment rates with a wide hospital network. Second, India has developed robust health data infrastructure to detect fraud, monitor overcharging, and guide investment into under-served regions. Third, the evolving health exchange platform, which integrates insurers, providers, and the government, can serve as the backbone for such a scheme. The proposed scheme would be designed by the government but run by licensed private insurers regulated by IRDAI. It would be voluntary and offered via a government-managed digital platform for enrolment, premium payment, claims processing, renewals, and servicing. Coverage options could range from ₹5 lakh to ₹1 crore. Crucially, the sum insured would increase every three years by 15-25% to counter inflation. All pre-existing conditions would be covered from day one. To avoid adverse selection—where mainly sick individuals enrol—a 25% co-payment would apply in the first year for non-accident claims. This co-pay would reduce by 6.25% each claim-free year, disappearing after four years. Those with frequent claims would still share some costs, ensuring fairness and sustainability. Premiums would be based only on age, gender, or family size—not health status. While insurers could limit sum insured for high-risk individuals or apply premium loadings, uniform rating by health condition would not be allowed. Hospital costs would be benchmarked to Ayushman Bharat rates, with a transparent mark-up for higher coverage, inflation, and reasonable hospital margins. Rates would be reviewed biennially. The government's digital platform would act as a single window for comparing plans, initiating claims, enabling cashless care, and renewing policies. A nominal platform fee of 3-5% would cover its operations and provide analytics to help insurers improve pricing, detect fraud, and reduce misuse. The scheme could serve as a standalone policy or a top-up to employer-provided health cover, allowing flexibility. To encourage insurer participation, early losses could be carried forward for 10-12 years. Additionally, the solvency margin requirement could be reduced from 150% to 100% for the first five years to support portfolio development. Comprehensive coverage at a lower cost This model offers several advantages. It provides comprehensive, inflation-adjusted coverage with no exclusions. Treatment costs would be lower due to pre-agreed hospital rates and minimal distribution costs. Consequently, premiums would be far more affordable than current retail products. The design rewards those who don't claim, while still covering those who do—striking a fair balance. Critically, the model does not require recurring government spending. A one-time partial premium contribution could be considered initially to accelerate enrolment. Regulatory oversight would remain with IRDAI—no new regulator is needed. Existing solvency and governance frameworks would apply. This proposal is not a replacement for existing schemes. Rather, it fills a critical gap in the healthcare financing ecosystem—protecting India's middle class from mounting health risks and costs. The government of India has an opportunity to catalyse this initiative. It builds on existing infrastructure, aligns with market principles, requires minimal fiscal support, and responds to a real need for millions of families. India can lead the world in creating a voluntary, digital-first, inflation-protected health insurance model for the middle class. The time to act is now. Kamesh Goyal is chairman of the Go Digit group of companies. Views expressed are his own.
Hindustan Times
3 hours ago
- Hindustan Times
Hyperpigmentation and dark spots reducing your skin's natural glow? Know 4 causes and how to treat them
Hyperpigmentation is one of the most frustrating obstacles to achieving that snatched, glowing skin. Even when your skin is relatively clear with no major breakouts, hyperpigmentation can still stand between you and your glow. If you feel like it's gatekeeping your main character moment, understanding the root causes is the first step to treating it effectively, steadily helping you get back on track to skin goals. Hyperpigmentation is a common skin concern that affects many individuals, causing uneven skin tone and dark patches. (Freepik) ALSO READ: Struggling with jaw and chin acne? Dermatologist says it could be hormonal, shares 5 ways to treat them Dr Rashmi Agrawal, skin specialist and founder and medical director of Skin International, Noida, shared with HT Lifestyle that hyperpigmentation has multiple contributors, ranging from environmental to physiological factors. Moreover, Indians have a higher likelihood of developing hyperpigmentation. She said, 'In India, uneven skin tone and hyperpigmentation are widespread dermatological concerns, impacting individuals across various age groups and skin types. These issues typically arise from excess melanin production, frequently caused by environmental exposure, hormonal changes, and day-to-day habits. Inconsistent skincare routines, such as skipping sunscreen, over-cleansing, or using harsh products, can further damage the skin and contribute to long-lasting unevenness." Dr Rashmi Agrawal shared a detailed guide with us, covering the essential reasons behind hyperpigmentation and what one can do to treat it: What are the main causes of hyperpigmentation? Hyperpigmentation is a common skin condition where the skin tone is darker than the surrounding areas. (Shutterstock) 1. Excessive sun exposure One of the leading contributors, particularly in India's tropical climate, is excessive sun exposure. Due to naturally higher melanin levels, Indian skin tends to hold on to melasma longer, making it more challenging to treat. Why: Ultraviolet (UV) rays activate melanocytes, the pigment-producing cells in the skin, resulting in tanning, dark patches, and discolouration. Ultraviolet (UV) rays activate melanocytes, the pigment-producing cells in the skin, resulting in tanning, dark patches, and discolouration. With our high UV index almost year-round, even brief periods in the sun without protection can significantly worsen pigmentation. 2. Pollution Pollution is aggravating for the skin. Why: Airborne toxins and particulate matter in densely populated cities can weaken the skin's natural barrier, triggering oxidative stress, inflammation, and eventually uneven pigmentation. 3. Hormonal changes Hormonal changes, particularly in women, also play a major role. Skin conditions like melasma, marked by dark patches across the forehead, cheeks, nose, and upper lip, are commonly linked to pregnancy, birth control pills, and thyroid imbalances. Due to naturally higher melanin levels, Indian skin tends to hold on to melasma longer, making it more challenging to treat. 4. Post-inflammatory hyperpigmentation (PIH) It develops after acne, minor injuries, or insect bites. PIH is often stubborn and can deepen if treated with inappropriate or harsh products. The rampant misuse of fairness creams, over-the-counter steroid ointments, and DIY home remedies often worsens pigmentation rather than resolving it. How to treat and prevent hyperpigmentation? At-home : At-home products like broad-spectrum sunscreen, vitamin C, niacinamide, and kojic acid are beneficial for prevention and maintenance. : At-home products like broad-spectrum sunscreen, vitamin C, niacinamide, and kojic acid are beneficial for prevention and maintenance. Clinical: In-clinic solutions such as chemical peels, microneedling, and laser therapies for faster and more visible results in persistent pigmentation. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Indian Express
4 hours ago
- Indian Express
As anti-obesity drug Wegovy launches in India, patients share experience using drugs like Mounjaro; doctors weigh in effectiveness
In 2018, V G, a 51-year-old man from Mumbai, was rushed to the hospital with accelerated hypertension and required aggressive medical intervention. With a history of pre-diabetes, high cholesterol, and a longstanding smoking habit, he was at significant cardiometabolic risk. At the time, he weighed 116 kg, with a BMI of 36.6 and an alarming waist circumference of 112 cm. Earlier this year, under medical supervision, V G began taking Mounjaro (tirzepatide) at a 5 mg dose. Within a few months, he lost 8 kg and reduced his waist circumference by 6 cm — an indication of significant visceral fat loss. His blood sugar levels also returned to the normal range, reversing his pre-diabetes. V G's journey shows that Injectable weight-loss drugs like Mounjaro and Wegovy are rapidly reshaping how India tackles obesity and related health issues. While Mounjaro has been available in India since March 2025, Wegovy – a brand name for high-dose semaglutide – was only launched in June. 'Yes, a lot of people are opening up to the use of anti-obesity medications. These drugs, both Wegovy and Mounjaro, are approved for chronic weight management and diabetes,' said Dr Rajiv Kovil, head of diabetology, Zandra Healthcare, and co-founder, Rang De Neela Initiative. Calling these drugs a 'game changer globally' and now in India, Varun Rattan, founder, Evolve Fitness, attributed the demand to 'rising obesity and intense cultural pressures'. Dr Prashant Hansraj Salvi, consultant, minimal invasive, bariatric and metabolic Surgery, Jupiter Hospital, Thane, said global interest in these drugs is being mirrored in India. 'While detailed local data is limited, the international trend clearly shows growing acceptance,' Dr Salvi said. Dr Vyankatesh Shivane, consultant diabetologist and metabolic physician, department of endocrinology, Jaslok Hospital and Research Centre, Mumbai, told that young Indians in their 30s and 40s are inquiring about these drugs. 'Social media has played a key role in spreading awareness about Mounjaro, Wegovy, and Ozempic. While Ozempic was originally used to treat type 2 diabetes, Mounjaro and Wegovy are now considered anti-obesity agents,' he said. Dr Shivane noted that according to Indian BMI guidelines, anyone with a BMI over 25 – or with associated risk factors like hypertension, cholesterol, diabetes or PCOD – may be eligible for these treatments. A 31-year-old woman, weighing 104.3 kg, began taking Mounjaro at 2.5 mg per week in April 2025. After completing the initial four-week course, the dosage was increased to 5 mg. 'It helped with appetite control and reduced cravings, especially for sugar and junk food,' she said. At her last consultation in May, she had lost almost 6 kgs. Mounjaro, Ozempic, and Wegovy belong to a class of glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed to treat diabetes and weight loss. They mimic a natural gut hormone (GLP-1) that stimulates insulin production and lowers blood sugar. 'Ozempic is the injectable semaglutide brand approved for diabetes, while Wegovy is the brand approved for obesity. Both have the same molecules, but dosing is slightly different. The dosing for Wegovy is higher because these drugs work at a lower dose as an anti-diabetic medicine and at a higher dose as an anti-obesity drug,' said Dr Kovil. Dr Shivane pointed out that the effectiveness of GLP-1 receptor agonists has become clear over the past 15 years. 'The first such drug marketed in India was liraglutide (Victoza), which caused around 8–10 per cent weight loss over six to eight months. Now we have newer, more potent versions like Ozempic, Wegovy, and Mounjaro,' Dr Shivane said. Dr Kovil said obesity contributes to conditions like diabetes, high cholesterol, blood pressure, sleep apnea, fatty liver, arthritis, and even 14 types of cancer. 'Drugs like Wegovy and Mounjaro can help people with obesity (without diabetes) lose 15–20 per cent of their weight, leading to remission of several related health issues and improving overall function,' said Dr Kovil. However, Dr Salvi stressed these are long-term treatments for medical obesity, not quick fixes or cosmetic solutions, and must be used under medical supervision. Ozempic is injectable semaglutide, but it is not available in India. Wegovy, now available in India, is semaglutide at a higher dose. 'Both Ozempic and Wegovy have been shown to cause 16–18 per cent weight loss in 52 weeks,' said Dr Shivane. Mounjaro contains tirzepatide, a dual receptor agonist (GLP-1 and GIP), and differs from semaglutide. 'This 'twincretin' effect has shown 22–25 per cent weight loss in clinical studies, more than either semaglutide-based drug,' said Dr Shivane. 'The dual action improves weight loss and blood sugar control,' said Dr Kovil. These drugs are typically injected once a week subcutaneously, like insulin. An oral version of semaglutide (Rybelsus) is also available but is less effective than the injectable form, said Dr Shivane. Dr Kovil concurred: 'When the two hormones are combined, it helps in better weight loss and better blood sugar control.' Administered once a week via subcutaneous injection, similar to insulin –– every Sunday, for example, and the patient can self-administer the injection –– these drugs are highly effective in aiding weight loss. Semaglutide is also available as an oral tablet called Rybelsus, said Dr Shivane. 'While it is more affordable and widely accepted, its weight loss efficacy is lower than injectable semaglutide (Ozempic or Wegovy), possibly due to absorption or dosing factors,' he said. These drugs reduce stomach emptying and suppress appetite. 'They also target brain centres that regulate cravings,' said Dr Kovil. Normally, when a person eats less, the body reduces its basal metabolic rate (BMR), making it harder to lose weight. 'But these drugs prevent that drop in BMR, helping patients continue to burn calories efficiently,' he said. Common side effects – with Mounjaro, Wegovy, and Ozempic – include nausea, vomiting, acidity, burping, hiccups, diarrhoea, abdominal pain, and appetite loss. 'Rarer complications include pancreatitis, retinal changes (necessitating eye exams), and increased risk of medullary thyroid carcinoma, especially for those with a family history,' Dr Shivane said, adding that before prescribing these medications, it's important to take a complete family history check. The 31-year-old patient reported mild weakness near the end of the week before her next dose, occasional dehydration, and a disrupted menstrual cycle, which lasted only 1.5 days. Patients with existing gastrointestinal issues or gallstones need extra caution. 'These drugs are not for everyone. A thorough medical and family history is essential,' said Dr Kovil. The upside is that these drugs have also undergone large cardiovascular outcome trials. 'They've shown significant reductions in all-cause mortality in high-risk patients with diabetes or heart/kidney issues. Hence, the US FDA has recommended their use in such high-risk patients,' said Dr Shivane. According to Dr Kovil, injectable therapies offer scalability and a non-invasive option compared to bariatric surgery, which is restricted to a smaller patient population. However, he warned that stopping these drugs often results in weight regain, typically 10–12 per cent, within a year. 'These medications are most effective when taken long-term and paired with lifestyle changes,' Dr Kovil said. For V G, the benefits extended well beyond glycemic control. 'His need for blood pressure medications reduced from three to two, and he cut his smoking habit in half, showing better overall health awareness,' said Dr Kovil. Experts reiterated that these medications are not magic bullets. 'They're not substitutes for healthy habits. Diet and exercise remain the cornerstone of any weight loss journey,' said Dr Kovil. The female patient admitted that she has not been able to follow workouts 'diligently due to my work and lifestyle,' but manages at least 25 minutes a day with Zumba, weights, pickleball/badminton. 'Previously, the workout was zero,' she said. Experts recommended a diet that is low in carbohydrates and fat, and high in fibre and protein. As for exercise, they recommended at least 45–60 minutes daily, including muscle-strengthening or cardio exercises like cycling, swimming, jogging, skipping, brisk walking, or stair climbing. It's also important to note that muscle loss is common if these medications are not paired with a balanced diet and expert guidance, making professional supervision key, said Dr Salvi. Rattan asserted that while these drugs take the edge off constant hunger, they increase the need for expert guidance. 'Nutritionists and trainers aren't being replaced, but their roles are evolving. They are your essential partners, ensuring this powerful tool translates into safe, healthy, and lasting results. The fat loss journey still needs them, just differently,' said Rattan. In clinical practice, Dr Shivane first recommends a three-month trial of diet and exercise. 'Only if the patient is compliant but doesn't lose weight, do I prescribe Mounjaro or Wegovy,' he said. Cost remains a significant barrier – monthly expenses can range from Rs 25,000 to Rs 40,000, and insurance doesn't cover it. 'None of these medications work in isolation. The best outcomes are seen when they're combined with strict diet and regular exercise,' Dr Shivane said. DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine. Jayashree Narayanan writes on fitness, health, aviation safety, food, culture and everything lifestyle. She is an alumnus of AJKMCRC, Jamia Millia Islamia and Kamala Nehru College, University of Delhi ... Read More
